Expert Interview
Looking at the Phase 3 Long-Term study of Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, for treatment of major depressive disorder.
Ticker(s): RLMD- Professor and Chairman, Department of Psychiatry at major US academic center.
- Treats 100 patients for Major Depressive Disorder and 30 patients with Bipolar II; able to discuss the literature to date on COMP360 Psilocybin Treatment for Bipolar II and CYB003 for Major Depressive Disorder.
- Areas of clinical and research interest include thet pathophysiology and treatment of anxiety disorders, developing novel pharmacologic agents for anxiety and mood disorders, and combining the use of cognitive-behavioral and pharmacologic therapies for refractory patients.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
